408 related articles for article (PubMed ID: 20350276)
1. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
[TBL] [Abstract][Full Text] [Related]
2. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
[TBL] [Abstract][Full Text] [Related]
3. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
[TBL] [Abstract][Full Text] [Related]
5. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
[TBL] [Abstract][Full Text] [Related]
9. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
[TBL] [Abstract][Full Text] [Related]
10. Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia.
Marshall GM; Kwan E; Haber M; Brisco MJ; Sykes PJ; Morley AA; Toogood I; Waters K; Tauro G; Ekert H
Leukemia; 1995 Nov; 9(11):1847-50. PubMed ID: 7475273
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
12. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
13. Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse.
Lal A; Kwan E; al Mahr M; Zhou L; Ferrara D; Tobias V; O'Gorman Hughes D; Haber M; Norris MD; Marshall GM
Mol Pathol; 1998 Oct; 51(5):277-81. PubMed ID: 10193523
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin gene rearrangement in detection of minimal residual disease in acute lymphoblastic leukaemia.
Nayyar A; Ahmed S
J Ayub Med Coll Abbottabad; 2013; 25(1-2):159-61. PubMed ID: 25098084
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
Kuang S; Gu L; Dong S; Cao Q; Xu C; Huang W; Su XY; Huang QH; Xie JX; Chen SJ; Chen Z
Cancer Genet Cytogenet; 1996 Jun; 88(2):110-7. PubMed ID: 8640718
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
[TBL] [Abstract][Full Text] [Related]
17. [Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].
Jia YP; Liu GL; Zhang LP
Zhonghua Er Ke Za Zhi; 2004 Aug; 42(8):600-4. PubMed ID: 15347448
[TBL] [Abstract][Full Text] [Related]
18. Genetic changes: relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukaemia.
Cole-Sinclair MF; Foroni L; Hoffbrand AV
Baillieres Clin Haematol; 1994 Jun; 7(2):183-233. PubMed ID: 7803899
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
Li AH; Forestier E; Rosenquist R; Roos G
Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
